Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms by Histologic Type 1Meningioma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Familial ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

tetulomab tetraxetan lu-177 2osimertinib 2fludarabine 2entinostat 2Pemetrexed 2Lutetium 2Carboplatin 2spartalizumab 1pembrolizumab 1nirogacestat 1interferon gamma-1b 1gilteritinib 1ficlatuzumab 1emvododstat 1denileukin diftitox 1atezolizumab 1Trabectedin 1Taxes 1Sunitinib 1Radiosurgery 1Oncolytic Virotherapy 1Nivolumab 1Lutetium-177 1Interleukin-2 1Interferon-gamma 1Immunotherapy 1Idarubicin 1HuMax-IL8 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms by Histologic Type × emvododstat × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡